Compare · CVRX vs RMD
CVRX vs RMD
Side-by-side comparison of CVRx Inc. (CVRX) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVRX and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $32.03B, about 157.0x CVRX ($204.0M).
- Over the past year, CVRX is up 4.3% and RMD is down 5.5% - CVRX leads by 9.8 points.
- CVRX has been more active in the news (5 items in the past 4 weeks vs 2 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 13 for CVRX).
- Company
- CVRx Inc.
- ResMed Inc.
- Price
- $7.83+1.56%
- $221.16+0.61%
- Market cap
- $204.0M
- $32.03B
- 1M return
- -15.90%
- -0.60%
- 1Y return
- +4.26%
- -5.52%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 5
- 2
- Recent ratings
- 13
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest CVRX
- CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
- SEC Form DEFA14A filed by CVRx Inc.
- SEC Form DEF 14A filed by CVRx Inc.
- CVRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- CVRx Reports Preliminary First Quarter 2026 Financial Results
- Chief Medical Officer Adamson Philip B. was granted 41,000 shares and sold $9,973 worth of shares (1,262 units at $7.90), increasing direct ownership by 182% to 61,578 units (SEC Form 4)
- CHIEF HUMAN RESOURCES OFFICER Morrison Gregory was granted 34,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Morrison Gregory
- PRES & CEO Hykes Kevin sold $61,349 worth of shares (7,763 units at $7.90) and was granted 159,000 shares, increasing direct ownership by 114% to 284,237 units (SEC Form 4)
- CHIEF MKTG & STRAT OFFICER Verrastro Paul was granted 45,000 shares and sold $10,146 worth of shares (1,284 units at $7.90), increasing direct ownership by 260% to 60,551 units (SEC Form 4)
Latest RMD
- Analyst initiated coverage on ResMed
- SEC Form 4 filed by Farrell Michael J.
- SEC Form 4 filed by Sandercock Brett
- SEC Form 4 filed by Farrell Peter C
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,252,902 worth of ResMed Common Stock (4,991 units at $251.03) (SEC Form 4)
- Director Farrell Peter C sold $520,440 worth of ResMed Common Stock (2,000 units at $260.22), decreasing direct ownership by 3% to 62,773 units (SEC Form 4)
- SEC Form 144 filed by ResMed Inc.